Skip to main content
Publications
Price M, Ravelo A, Sae-Hau M, Torney PA, Gonzalez V, Weiss ES, Mansfield C, Mange B, Comenencia Ortiz E, Masaquel A, Lamont Dawson K. Patient-reported disease burden in chronic lymphocytic leukemia, diffuse large B-cell lymphoma, and follicular lymphoma: results from a national patient advocacy survey. Poster presented at the 2019 ASCO Annual Meeting; May 2019. [abstract] J Clin Oncol. 2019 May 26; 37(15_suppl):e18198. doi: 10.1200/JCO.2019.37.15_suppl.e18198
Mansfield C, Ekwueme DU, Tangka FKL, Brown DS, Smith JL, Guy, Jr GP, Li C, Hauber B. Colorectal cancer screening: preferences, past behavior, and future intentions. Patient. 2018 Nov 5;11(6):599-611. doi: 10.1007/s40271-018-0308-6
Saif WM, Parikh R, Ray D, Kaye JA, Kurosky SK, Thomas K, Beveridge T, Mirakhur B, Lubeck CA, Nagar SP, Soares H. The sequencing of lanreotide (LAN) after octreotide LAR (OCT) for the treatment of gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Poster presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; June 1, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018 Jun 1; 36(15_suppl):e16174. doi: 10.1200/JCO.2018.36.15_suppl.e16174
Winfree KB, Ainsworth C, Njue A, Molife C, Lyall M, Jen MH, Bittoni M, Heyes A, Carbone DP. Novel antiangiogenic drugs, immune checkpoint inhibitors, and chemotherapy in patients with aNSCLC who have aggressive disease: a systematic review. J Clin Oncol. 2018 May 16;36(15_suppl):e21120-e. doi: 10.1200/JCO.2018.36.15_suppl.e21120
Pollard DJ, Brennan A, Dixon S, Waugh N, Elliott J, Heller S, Lee E, Campbell M, Basarir H, White D, REPOSE group. Cost-effectiveness of insulin pumps compared with multiple daily injections both provided with structured education for adults with type 1 diabetes: a health economic analysis of the Relative Effectiveness of Pumps over Structured Education (REPOSE) randomised controlled trial. BMJ Open. 2018 Apr 7;8(4):e016766. doi: 10.1136/bmjopen-2017-016766
Fernandez-Martos C, Pericay C, Losa F, Garcia-Carbonero R, Layos L, Rodriguez Salas N, Martin M, Alonso V, Vera R, Gallego J, Capdevila J, Salud A, Nogue M, Maurel J, Guasch I, Montagut Viladot C, Lopez-Lopez C, Canas MA, Declara IM, Garcia-Albeniz X. Randomized phase II study comparing induction (I) mFOLFOX6 with or without aflibercept followed by chemoradiation (CRT) and total mesorectal excision (TME) in high risk-rectal cancer. GEMCAD 14-02 trial. Poster presented at the 2018 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2018. Chicago, IL. [abstract] J Clin Oncol. 2018; 36(2018):e3518.
Vilanova MB, Falguera M, Marsal JR, Rubinat E, Alcubierre N, Castelblanco E, Granado-Casas M, Miro N, Mollo A, Mata-Cases M, Franch-Nadal J, Mauricio D. Prevalence, clinical features and risk assessment of pre-diabetes in Spain: the prospective Mollerussa cohort study. BMJ Open. 2017 Jun 11;7(6):e015158. doi: 10.1136/bmjopen-2016-015158
Telfort J, Trivedi MS, Yi HS, Colbeth H, Vanegas A, Vargas J, Sandoval R, Wood J, Dimond J, Finkelstein J, Kukafka R, Crew KD. Implementing decision support for breast cancer chemoprevention in primary care. J Clin Oncol. 2017 May;35(15 Suppl):e13038. doi: 10.1200/JCO.2017.35.15_suppl.e13038
Taylor S, Demeyin (Nuabor) W, Muls A, Ferguson C, Farnell DJ, Cohen D, Andreyev J, Green J, Smith L, Ahmedzai S, Pickett S, Nelson A, Staffurth J. Improving the well-being of men by Evaluating and Addressing the Gastrointestinal Late Effects (EAGLE) of radical treatment for prostate cancer: study protocol for a mixed-method implementation project. BMJ Open. 2016 Oct 3;6(10):e011773. doi: 10.1136/bmjopen-2016-011773
Maurel J, Fernandez-Martos C, Martin-Richard M, Alonso V, Mendez JC, Salud A, Pericay C, Aparicio J, Gallego J, Carmona A, Casado E, Manzano H, Horndler C, Rubini M, Cuatrecasas M, Garcia-Albeniz X, Feliu J. Prospective biomarker validation trial evaluating the prognostic role of the combined expression of phospho-insulin growth factor receptor-1 and matrilysin in KRAS (exon 2) wild-type (WT) metastatic colorectal cancer (mCRC) patients treated with FOLFOX-6 plus panitumumab as first-line therapy [PULSE trial (GEMCAD 09-03)]. Poster presented at the 2016 ASCO Annual Meeting; January 23, 2016. Chicago, IL. [abstract] J Clin Oncol. 2016 Feb; 34(4_Suppl):583. doi: 10.1200/jco.2016.34.4_suppl.583
Casulo C, Byrtek M, Dawson KL, Zhou X, Farber CM, Flowers CR, Hainsworth JD, Maurer MJ, Cerhan JR, Link BK, Zelenetz AD, Friedberg JW. Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the National Lymphocare Study. J Clin Oncol. 2015 Aug 10;33(23):2516-22.
Stenehjem DD, Tyczynski JE, Unni SK, Bauer H, Sainski A, Deka R, Shauehamer M, Gutierrez LP, Kaye JA, Telford C, Brixner DI, Biskupiak DI. Evaluation of BRCA mutation (BRCAm) testing patterns, clinical characteristics and overall survival (OS) in breast cancer (BC) patients over a 20-year period. J Clin Oncol. 2015 May 29;33(15_suppl):e12518. doi: 10.1200/jco.2015.33.15_suppl.e12518
Alonso-Espinaco V, Marmol M, Alonso V, Escudero P, Horndler C, Ortego J, Gallego R, Garcia-Albeniz X, Jares P, Cuatrecasas M, Jose Lozano J, Castells A, Maurel J. Influence of BRAF mutations and RAC1b/RAC1 mRNA expression ratio on outcome in patients with metastatic colorectal cancer (mCRC) treated with first-line chemotherapy. Poster presented at the 2012 ASCO Annual Meeting; June 4, 2012. Chicago, IL. [abstract] J Clin Oncol. 2012 Jun; 30(15_Suppl):3553. doi: 10.1200/jco.2012.30.15_suppl.3553
Kiladjian J-J, Gisslinger H, Passamonti F, Niederwieser D, Mendelson E, Sirulnik LA, Copley-Merriman K, Zhou X, Levy RS, Knoops L, Cervantes F, Barbui T, Barosi G, Vannucchi AM, Harrison CN. Health-related quality of life (HRQoL) and symptom burden in patients (Pts) with myelofibrosis (MF) in the COMFORT-II study. Poster presented at the 2012 Annual Meeting of the American Society of Clinical Oncology (ASCO); June 1, 2012. Chicago, IL. [abstract] J Clin Oncol. 2012 Jun 1; 30(15_suppl):6626. doi: 10.1200/jco.2012.30.15_suppl.6626